Page 96 - D. Cancer biology
P. 96
[D. Cancer biology-63]
Enhance the efficacy of oncolytic virus in drug-resistant
ovarian cancer
Seoyul Lee¹, Daekyoung Kim¹, Minjoo Shin¹, Yeeun Kim¹, Jaeho Kim¹˙*
¹School of Medicine, Pusan National University, Yangsan-si 50612, Korea
Recurrent ovarian cancer is known to be caused by drug-resistant cancer cells after chemotherapy. To overcome
recurrent ovarian cancer, it needs to develop anti-cancer treatments that can eradicate drug-resistant cancer cells.
In this study, we isolated a drug resistant cell line of A2780 ovarian cancer cells by subculture in the presence of
Doxorubicin. The Doxorubicin-resistant A2780 cells (A2780-R) exhibited higher resistance to Doxorubicin than A2780
cells. We next investigated the possibility of an oncolytic vaccine virus (OVV) for the death of conventional
chemotherapy-resistant cells. Interestingly, A2780-R cells exhibited reduced virus replication and cell death
compared to A2780 cells. Several cell signaling mechanisms were changed in A2780-R compared to A2780 cells. In
the treatment of inhibitors for these signaling factors, an inhibitor D increased the replication of OVV and cell death
in A2780-R cells. In addition, the phosphorylation of STAT3 was increased during inhibitor D treatment, and the
increase in OVV replication by inhibitor D treatment was abrogated during treatment of an STAT3 inhibitor. These
results suggest that the pharmacological attenuation of the target signal by inhibitor D augments oncolytic efficacy
of OVV in the drug-resistant ovarian cancer.
